Lotus Signs an Exclusive Commercialization Agreement with CKD for Biosimilar Darbepoetin Alfa

Shots:  

• Lotus to get an exclusive commercialization right of biosimilar Darbepoetin alfa in Taiwan and Southeast Asian markets
• The collaboration allows the Lotus to re-emphasize its focus on nephrology as a core therapy in key Asian markets by ensuring the access to quality medication and maintains growth momentum with another addition to its biosimilar pipeline
• Darbepoetin alfa from CKD is the 5th biosimilar product Lotus has in the pipeline. Lotus has the rights to commercialize bevacizumab and adalimumab in multiple Asian countries and has submitted MAA for trastuzumab in Korea, and teriparatide in both Taiwan and Thailand

Click here ­to­ read full press release/ article | Ref: Lotus | Image: Lotus